H 4 conformation is proposed as the exploded transition state.
Newly synthesized membrane and secretory proteins are commonly glycosylated as they enter the lumen of the endoplasmic reticulum (ER) 1 (1) . The protein-linked glycans are immediately trimmed, and the resulting structures subsequently serve as ligands for the luminal lectin chaperones, calnexin and calreticulin, which act in conjunction with other chaperones and thiol disulfide oxidoreductases to help facilitate protein folding, oligomerization, and disulfide bond formation (2) . Release from the chaperones and packaging into anteriograde transport vesicles is generally accomplished only upon completion of the folding process. In contrast, proteins that fail to fold continually re-engage the chaperone machinery either until folding is achieved or until the nascent glycoproteins acquire a signal for disposal through the ER-associated degradation (ERAD) pathway (3) . Many normal proteins, as well as many "defective" proteins in loss-of-function human genetic diseases, have delayed rather than defective folding kinetics that result in the premature disposal of the newly synthesized polypeptides (2) . Thus, the percentage of transported functional protein is defined by a competition between the kinetics of conformational maturation versus the rate of acquiring the targeting signal for protein disposal.
The present model for ERAD invokes the specific cleavage of a single mannose residue from the Man 9 GlcNAc 2 glycan processing intermediate by the slow acting enzyme, ER mannosidase I (ERManI), as a rate-limiting initiation step for targeting incompletely folded glycoproteins for disposal (4) . The trimmed oligosaccharide, in the context of an unfolded polypeptide, is subsequently recognized by a collection of luminal ER lectins, termed EDEMs, which are nonhydrolytic homologs of ERManI (2, (5) (6) (7) (8) . The nature of the complex interactions between misfolded glycoproteins, EDEMs, and other ER-associated components has still not been entirely resolved, but present models envisage a "handing off" of the ERAD substrate to the Sec61 translocon pore complex for retrotranslocation and subsequent proteasomal degradation (2) .
ERManI, EDEMs, and a collection of Golgi processing hydrolases, termed Golgi ␣-mannosidases IA, IB, and IC, are all members of glycosylhydrolase (GH) family 47 (9, 56) . The hydrolytic members of this family have unique branch specifici-ties that are required for the complete trimming to the key Man 5 GlcNAc 2 intermediate structures necessary for maturation into complex type glycans on cell surface and secreted glycoproteins (9 -11) . Despite sequence similarities with family 47 hydrolases, EDEM family members appear to lack hydrolase activity, but they are proposed to accomplish their lectin function in ERAD by a mechanism analogous to glycan recognition during catalysis by the true hydrolases (2, (5) (6) (7) (8) . Thus, understanding how this family of enzymes and lectins accomplish their functions will provide insights into the rate-limiting decision between glycoprotein maturation and disposal in the secretory pathway.
The two standard mechanisms for glycosidase-mediated bond hydrolysis both involve the direct protonation of the glycosidic oxygen by an enzyme-associated catalytic acid and the attack of the anomeric carbon atom by a nucleophile (12) . Glycosidases with retaining mechanisms generally employ an enzyme-associated nucleophile, usually a Glu or Asp carboxylate side chain, resulting in the transient formation of an enzyme-linked intermediate that is subsequently cleaved by an incoming general base-activated water molecule to result in a released glycone that retains the configuration of the original glycosidic linkage. In contrast, glycosidases with inverting mechanisms employ the direct nucleophilic attack by a general base-activated water molecule to result in inversion of configuration of the released glycone. Both mechanisms require the formation of a transition state carrying a considerable positive charge delocalized between the anomeric center (C-1) and the ring oxygen (O-5) (12) (13) (14) . The resulting partial double bond character of the C-1-O-5 bond requires co-planarity of C-5, O-5, C-1, and C-2 at or near the transition state. Among the potential pseudorotational conformational itineraries for sugar pyranose ring interconversions, there are four potential conformations where the planarity of C-5, O-5, C-1, and C-2 is satisfied ( Fig. 1 (14 -18) . Evidence favoring these conformations has come from the analysis of x-ray structures of target enzymes with trapped covalent intermediates using fluorinated substrate analogs (for retaining glycosidases), with enzymebound nonhydrolyzable substrate mimics, or with natural substrates in combination with active site mutants (14 -18) . Of the four possible coplanar transition states, only the 3 H 4 conformation has not yet been identified as an intermediate in any glycosidase mechanism.
Family 47 ␣-mannosidases from a variety of species have been extensively studied in regard to enzyme kinetics, substrate specificity, and structural analysis (9 -11, 19 -23) . Mutagenesis studies of potential residues involved in Ca 2ϩ binding and catalysis have also been carried out for S. cerevisiae ERManI (24) , but these studies predated the structural determination of either the yeast (21) or human (20) enzymes, and the roles of these residues in catalysis and substrate binding have not been revisited. Two classes of ␣-mannosidase co-complexes have been characterized by x-ray diffraction. Putative enzyme-glycan product co-complexes have been isolated for both ER and Golgi family 47 hydrolases, revealing the structural basis for branch specificity by these enzymes (19, 21) . In addition, co-complexes between ERManI and the inhibitors, kifunensine and 1-deoxymannojirimycin (dMNJ), have revealed several unprecedented aspects of glycone binding and hydrolysis by this family of enzymes (20) . Both inhibitors were found to bind in the Ϫ1 subsite at the core of the enzyme (␣␣) 7 barrel catalytic domain (Fig. 2) in the equivalent of (14) . The red boxed region illustrates the potential 3 H 4 transition state for glycosylhydrolase family 47 ␣-mannosidases bracketed by the 4 C 1 chair conformation found for the ERManI⅐dMNJ co-complex and the 3 S 1 conformation of the ERManI-thiodisaccharide co-complex described here.
an unusual high free energy 1 C 4 conformation facilitated both by a direct coordination of the inhibitor O-2Ј and O-3Ј hydroxyls with an enzyme-associated Ca 2ϩ ion and by a matrix of hydrogen bonds and hydrophobic interactions. A novel inverting glycosidase mechanism was proposed where the water nucleophile was one of the ligands directly coordinated with the enzyme-bound Ca 2ϩ ion, and the catalytic acid was proposed to act indirectly in a through-water protonation of the glycosidic oxygen (20) . The unusual nature of this proposed mechanism precluded an unambiguous identification of the catalytic acid and base residues.
We describe here the kinetics and binding characteristics of potential catalytic mutants as well as a co-complex of ERManI with a nonhydrolyzable thiodisaccharide pseudosubstrate. These data demonstrate the roles of various active site residues as well as the novel conformational itinerary during glycoside bond hydrolysis. (25) . We chose an alternate strategy using the alternative key coupling reaction of methyl 3-Obenzyl-4,6-O-benzylidene-2-S-thioacetyl-␣-D-mannopyranoside with 2,3,4,6-tetra-O-acetyl-D-mannopyranosyl bromide and characterized the synthetic product by NMR as described in the Supplementary Data.
MATERIALS AND METHODS

Synthesis of Methyl-2-S-(␣-D-mannopyranosyl)-2-thio-␣-D-mannopy-
Mutagenesis, Expression, and Purification of Human ERManI-The expression and purification of the human ERManI catalytic domain has been described previously (20, 26) . The cDNA encoding ERManI in the pPICZ␣A vector (Invitrogen) was used to perform site-directed mutagenesis using the QuikChange™ mutagenesis kit from Stratagene (La Jolla, CA) based on the sequence of human ERManI (GenBank TM accession number AF145732). The full coding region of each mutant was sequenced to confirm that only the desired mutation was generated. The plasmid constructs were then used to transform the Pichia pastoris strain X-33, and zeocin-resistant colonies were screened for ERManI expression by performing Western blots using conditioned medium from induced cultures as previously described (20) . ERManI was detected using a rabbit polyclonal anti-human ERManI antibody generated to the recombinant wild type enzyme, and the antibody was detected using a peroxidase-conjugated anti-rabbit IgG secondary antibody. Mutant enzymes were expressed in 1-liter shake flask cultures by induction in BMMY media, and the enzyme was purified from the conditioned media as previously described (20) .
Man 9 GlcNAc 2 -PA and Glycopeptide Preparation-Crude soybean agglutinin was extracted from soy flour by acid and ammonium sulfate precipitation (27) and was subsequently denatured, reduced, and carboxyamidomethylated in 8 M guanidine HCl containing 50 mM dithiothreitol and 100 mM iodoacetamide (28) prior to proceeding to elastase digestion (29) . The Man 9 GlcNAc 2 -glycopeptide was recovered by affinity chromatography using concanavalin A-Sepharose and further purified by HPLC on a Cosmosil C18 column (30) for SPR studies. For enzyme assays, Man 9 GlcNAc 2 was liberated from the peptide by peptide:N-glycosidase F digestion (31) and derivatized with pyridylamine (32) .
Enzyme Assays-The purified wild type and mutant enzymes were assayed for ␣1,2-mannosidase activity using pyridylamine-tagged Man 9 GlcNAc 2 (Man 9 GlcNAc 2 -PA) as substrate (32) . The enzyme reactions (20 l) were carried out in 96-well plates by adding 10 l of enzyme in 300 mM NaCl and 10 mM CaCl 2 to a mixture of 5 l of 4ϫ universal buffer (80 mM succinic acid, 80 mM MES, 80 mM HEPBS, 80 mM HEPES, and 80 mM CHES adjusted to pH with 5 M NaOH) and 5 l of substrate. The reactions were performed at 37°C for the indicated times and stopped by the addition of 20 l of 1.25 M Tris-HCl (pH 7.6) to the reaction mixture. The enzymatic products were resolved and quantitated using a Hypersil APS-2 NH 2 -HPLC column (32) . Initial rates (v) for the enzymes were determined at various substrate concentrations ranging from 10 to 300 M. The catalytic coefficient (k cat ) and Michaelis constant (K m ) values were determined by fitting initial rates to a Michaelis-Menten function by nonlinear regression analysis using SigmaPlot (Jandel Scientific, San Rafael, CA)). k cat /K m values were derived from reciprocal plots of v and [S] where needed.
pH Rate Dependence Analysis-Values for k cat and K m were determined from initial rates of enzyme reactions in the pH range from 4 to 10 using the 1ϫ universal buffer described above. Plots of log(k cat /K m ) versus pH were used to estimate values of the macroscopic enzyme ionization constants (pK E1 and pK E2 ) by linear extrapolation of the acidic and basic limbs of the curve (Fig. 3) .
Binding Studies by Surface Plasmon Resonance (SPR)-SPR analyses were conducted using a Biacore 3000 apparatus (Biacore AB, Piscataway, NJ). Recombinant ERManI was immobilized on the SPR chip surfaces at 25°C by the amine coupling method (34) . The flow cells were activated by injecting a mixture of 50 mM N-hydroxysuccinimide and 200 mM 1-ethyl-3-(dimethylaminopropyl)carbodiimide over the CM5 sensor chip surface for 7 min at 5 l/min. The recombinant proteins (30 g/ml) prepared in 10 mM sodium succinic acid (pH 6.0) were passed through a 0.2-m polyvinylidene difluoride filter (Millipore Corp.) and diluted in the same buffer to obtain a concentration of 5 g/ml prior to injection onto the activated surface. The desired immobilization level was achieved by specific contact time. The remaining reactive groups were blocked by injection of 1 M ethanolamine-HCl at pH 8.5 for 7 min at 5 l/min. The immobilization efficiency for ERManI was about 2500 RU/min at a flow rate of 5 l/min in HPB-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.01% polysorbate P20) at 25°C. Mock derivatized flow cells served as reference surfaces. The binding analyses were performed at 10°C with a continuous flow (30 l/min) of running buffer (10 mM MES, pH 7.0, 300 mM NaCl, and 5 mM CaCl 2 ). Analytes were prepared in running buffer by 2-fold serial dilution to obtain an appropriate concentration range. A concentration series of Man 9 GlcNAc 2 -glycopeptide (0.4 -400 M) was analyzed over a low density immobilization surface of recombinant protein (3000 RU), whereas disaccharides (16 -1000 M) and dMNJ (2-1000 M) were analyzed over a high density immobilization surface of recombinant protein (10,000
Model for the structure and catalytic residues for human ERManI used in mutagenesis studies described in this paper. The structure of the co-complex between human ERManI and dMNJ (PDB 1FO2 (20) ) was used to select potential residues involved in catalysis. The end (A) and side (B) views of the human ERManI ribbon diagram display the (␣␣) 7 barrel structure with the inhibitor (dMNJ; stick representation) bound in the core of the barrel directly coordinated to the protein-bound Ca 2ϩ ion (blue space fill) as highlighted by the blue circle. The residues examined in this study are shown in the stereo diagram (C), where the stick representation of dMNJ is shown in yellow, the Ca 2ϩ ion is shown as blue space fill, and the relevant residues described throughout are shown as white stick diagrams. Crystallization and X-ray Diffraction-In an effort to obtain higher resolution crystal structure data than was previously obtained for human ERManI (20) , a sparse matrix screen (36) was performed with the Crystal Screen HT™ from Hampton Research, carried out using an Oryx 6 crystallization robot (Douglas Instruments) in Nunc HLA plates. The crystallization drop was prepared by mixing equal volumes (0.5 l) of the protein and the screening solutions (final protein concentration 10 mg/ml) and sealed with paraffin oil (15 l). The plate was then overlaid with a mixture of silicone and paraffin oils (30:70) (37, 38) and kept at 18°C. Crystal formation was monitored after 3 days. Additive screening was carried out by mixing equal volumes (0.5 l) of the protein solution, the optimized crystallization solution (24% (w/v) polyethylene glycol 4000, 100 mM MES/NaOH, pH 6.0, and 50 mM ammonium sulfate), and 3ϫ additive screen components (Hampton Research, catalog number HR2-428). The addition of 1,4-butanediol was found to produce the best crystals and improved diffraction to beyond 1.35 Å for the native enzyme (data not shown). Since we had a limited supply of the thiodisaccharide substrate analogue, direct co-crystallization was attempted using the above conditions without further optimization.
For co-crystallization, the thiodisaccharide (100 mM in H 2 O) was added to the protein solution to yield 10 mg/ml recombinant protein, 20 mM MES, pH 7.0, 150 mM NaCl, 5 mM CaCl 2 , 750 mM NDSB 201, and 50 mM thiodisaccharide and incubated for 2 h at room temperature prior to crystallization. A hanging drop was prepared over 1 ml of mother liquor containing 24% (w/v) polyethylene glycol 4000, 100 mM MES/NaOH, pH 6.0, 50 mM ammonium sulfate, and 10% (v/v) 1,4-butanediol. The crystallization drop contained 1.5 l of protein/ligand solution and 1 l of mother liquor. Crystals formed within 4 h at 25°C and were mounted and flash-frozen 1 day later using 10% glycerol as cryoprotectant. Although the single co-crystals grown by this method were considerably smaller in size than that of the native crystals, one of the crystals produced diffraction data that could be scaled to 1.41 Å with good statistics and completeness (Table III) .
Crystals were examined using an ACTOR/Director automated crystal-screening system (Rigaku/MSC) consisting of an FR-D high intensity rotating anode, a Max-Flux confocal optics, an AFC-9 four-axis goniometer, and a Saturn 92 CCD detector. Complete diffraction data were collected at the Advanced Photon Source, beam line 22ID, using a MARCCD-225 detector and a crystal-to-detector distance of 130 mm. A total of 360 1°oscillation images were recorded. Integration and scaling were performed with the HKL software suite (39) . The structure was solved by molecular replacement using the program EPMR (40) and Protein Data Bank entry 1FMI (20) as a search model. Rebuilding (Xfit (41)) was repeatedly iterated with refinement (Refmac5 (42-44)) and validation (MOLPROBITY (45)). Diffraction analysis indicated that both native and co-crystals belong to space group P1 in contrast to the prior crystal form (P3 1 21) for native and inhibitor-bound human ERManI (20) . Matthews coefficients (46) and structure determination indicated a single molecule per asymmetric unit. All of the unit cell constants between the co-crystal and the native enzyme were within 0.5 Å or 0.4°with the exception of angle ␣, where the co-crystal was calculated to be significantly larger than that of the native crystal (89.5°for the co-crystal and 66.2°for the native crystal). Although the difference in the unit cell constant suggests a significant impact of the presence of thiodisaccharide on crystal packing, there were no significant differences in overall protein structure between native crystal (data not shown), co-complex structures, or the prior crystal forms (20) .
For the calculation of the F o Ϫ F c electron density map, inhibitor atoms were deleted from the model. Remaining model atoms were displaced randomly by an average 0.3 Å, and their temperature factors were randomly altered by an average of 3 Å 2 with the program Moleman (47) . Amplitudes and phases for the weighted difference map were calculated after 10 cycles of REFMAC5 (43) (Fig. 2) . Each of these residues was individually altered by mutagenesis (D463N, E330Q, E599Q, R334A, and H524A) along with some of the combinations of double mutants and expressed in P. pastoris as secreted catalytic domains (19, 20) . Expression of R334A was not detected in the culture media and was not characterized further.
All of the mutants had diminished k cat values relative to wild type ERManI (Table I ), but the mutations had a relatively minor impact on K m (variation of Ͻ2.4-fold). The H524A mutant showed the least change in k cat (4.3-fold reduction), whereas other mutants varied from a 44-fold reduction (E330Q) to a 10 5 -fold reduction (E599Q) ( Table I) . Double mutants of E599Q with either E330Q or D463N showed significant reductions in k cat and slight increases in K m consistent with the dominant effect of the E599Q single mutant. pH rate analysis indicated that there was no significant change in pH optimum (Ͻ0.5 pH units) for any of the mutants except for E330Q, which displayed a reduction in pH optimum of ϳ1.8 units (Table I) . A plot of log(k cat /K m ) versus pH confirmed that the E330Q mutant had a major shift of ϳ1.8 pH units for the peak value in the plot (Fig. 3) . Linear approximations for the enzyme ionization constants (pK E values) for the acidic and basic limbs of the curve indicated that both values decreased in the E330Q mutant, with a 0.8-pH unit drop on the acidic limb and a 1.3-pH unit drop on the basic limb. These data indicate that the mutation causes a global change in the ionization state in the active site, influencing both the acidic and basic limbs of the pH curve. An effect on the basic limb of the curve would be consistent with an influence on the ionization of a potential general acid as a proton donor in the catalytic mechanism.
Glycan Binding Affinity Measurements to Human ERManI-In addition to kinetic analysis, the binding affinities between Man-␣1,2-Man-containing glycans and recombinant wild type and mutant forms of ERManI were examined by SPR, including high mannose oligosaccharides, a nonhydrolyzable thiodisaccharide analog, and an equivalent O-disaccharide. The on-rates (k a ) and off-rates (k d ) for binding of Man 9 GlcNAc 2 -glycopeptide to the wild type and E599Q mutant were too fast for accurate measurement by SPR, but the equilibrium dissociation constant (K D ) could be derived from the equilibrium values of the binding sensorgrams (Fig. 4, inset plots) . In contrast, the E330Q mutation displayed significantly slowed onand off-rates for all of the ligands, allowing the measurement of k a and k d and thus the equilibrium dissociation constant (K D ϭ k d /k a ) from both the kinetic and equilibrium binding data. The resulting data (Table II) indicate that the E330Q mutant had an ϳ100-fold increase in binding affinity for the Man 9 GlcNAc 2 -glycopeptide ligand with a virtually unchanged affinity for dMNJ. These values, in combination with slowed on-and offrates and the decreased k cat observed for the E330Q mutant indicate that the replacement of this carboxyl side chain with an uncharged isosteric amide causes a significantly reduced catalytic turnover, slower binding kinetics, and higher binding affinity for the substrate without altering the affinity for the glycone residue. In contrast, the E599Q mutant had a 4-fold weaker binding affinity than the wild type enzyme for Man 9 GlcNAc 2 -glycopeptide and an ϳ1000-fold reduction in binding affinity to dMNJ (Fig. 4 and Table II ), indicating that the mutation results in both a significant drop in k cat and an unfavorable binding of the glycone residue.
The D463N mutant revealed a surprising difference in binding characteristics between the Man 9 GlcNAc 2 -glycopeptide and dMNJ ligands. The binding affinity of dMNJ for the D463N mutant was reduced ϳ73-fold (Table II) , but binding to the Man 9 GlcNAc 2 -glycopeptide (Fig. 4) as well as the disaccharide ligands (data not shown) was virtually eliminated. These data are consistent with a role for this latter residue in binding the substrate in the ϩ1 subsite as supported by the ERManIthiodisaccharide co-crystal structure described below. Table II) or the E330Q mutant (data not shown) were significantly slower than the Man 9 GlcNAc 2 -glycopeptide, and both displayed lower equilibrium binding affinities. The onand off-rates were significantly different for the two disaccharides, but the equilibrium dissociation constant (K D ) was only ϳ5-fold lower for the thiodisaccharide versus the O-glycoside. Similarly, the IC 50 for inhibition of human ERManI by the thiodisaccharide (ϳ200 M) was lower than the K m for the O-glycoside substrate (ϳ2 mM). These data, in combination with the NMR data above, indicate that the solution behavior and binding of the thiodisaccharide to ERManI is likely to be similar to those of the O-glycoside substrate.
Disaccharide Binding to Human ERManI-Methyl-2-S-(␣-D-
Co-complex Structure of ERManI with the Thiodisaccharide Analog-Co-crystallization of recombinant human ERManI with the thiodisaccharide analog resulted in crystals that diffracted beyond 1.4 Å (Table III) , and the structure of the cocomplex was solved by molecular replacement using the structure of human ERManI (Protein Data Bank code 1FMI (20) ) as the probe. The structure revealed the anticipated (␣␣) 7 barrel catalytic domain (Fig. 2) (20) with an extra density corresponding to the thiodisaccharide in the proposed Ϫ1 and ϩ1 subsites (Fig. 5A) . As anticipated, the C-S bond lengths for the thiodisaccharide were both ϳ1.8 Å, significantly greater than the standard ϳ1.4 Å C-O bonds in a glycosidic linkage. Modeling of Man-␣-O-CH 3 in the ϩ1 subsite revealed an unambiguous 4 C 1 conformation, whereas the conformation of the sugar occupying the Ϫ1 subsite was clearly distorted (Fig. 5, A and B) . The hydroxyls associated with C-3 and C-4 as well as the C-5-C-6 linkage were in axial orientations, and the O-2Ј hydroxyl was equatorial, representing identical positions compared with the 1 C 4 conformation adopted by dMNJ when bound in the Ϫ1 subsite (20) . However, the positions of C-1, O-5, and C-5 of the Ϫ1 residue were clearly distorted from a 1 C 4 chair into a 3 S 1 a Assay data were fit to generate a bell-shaped curve to yield a pH optimum with an S.E. value of less than 0.1 pH unit. b The pH optimum of the E330Q mutant is 5.3, but the kinetic constants for the enzyme assayed at pH 7.1 (pH optimum for wild type enzyme) are also shown in parentheses.
skew boat conformation (Fig. 5B) . The altered position of C-5 resulted in a corresponding change in the position of C-6; however, a rotation of the C-5-C-6 bond resulted in a nearly identical position of the O-6Ј hydroxyl for hydrogen bonding to O-⑀1 of Glu 599 and NH1 of Arg 597 . Thus, C-1, O-5, C-5, and C-6 are the only atoms that were significantly different in position from the 1 C 4 chair of the dMNJ co-complex structure (20) , and none of these atoms directly interact with the enzyme in the Ϫ1 (Fig. 6) . The movements for C-5, O-5, and C-1 would be ϳ0. 4 Fig. 7 and Table IV ).
The positions of the proposed catalytic base, Glu 599 , and the water nucleophile, W5, as well as the protein-associated Ca 2ϩ ion are essentially unchanged from the free enzyme or the ERManI⅐dMNJ co-complex (Table IV) (20) . The distances from Glu 599 to W5 (2.7 Å) and from W5 to C-1 of the sugar in the Ϫ1 site (3.2 Å) would indicate that the water nucleophile could be activated by the Glu 599 base for nucleophilic attack. The distance from W5 to the C-1 of the glycone would be expected to be even less at the 3 H 4 transition state conformation.
DISCUSSION
Class 1 ␣-mannosidases (family 47 glycosidases (56)) are key enzymes in the maturation of N-glycans in the secretory pathway as well as playing key roles in defining the timing and recognition for disposal of misfolded proteins by ER-associated degradation (2, 4 -8, 49, 50) . Previous structural studies on the co-complexes between human ERManI and the inhibitors, dMNJ and kifunensine, implicated three residues in proximity to the glycosidic bond, Asp 463 , Glu 330 , and Glu 599 , as potential catalytic residues (Fig. 2) (20) . In addition, computational docking studies of monosaccharides and disaccharides in the active site of S. cerevisiae ERManI have suggested that the equivalents of Glu 330 and Glu 599 act as the catalytic acid and base residues, respectively, and that an E 4 conformation is the likely transition state (48). The mechanism proposed from these structural studies included several elements not common for inverting glycosidases, including the involvement of an unusual high free energy intermediate adopting a 1 C 4 conformation, a through-water protonation of the glycosidic oxygen, and a water nucleophile that was also directly coordinated to an enzyme-associated Ca 2ϩ ion (20) . In an effort to understand the mechanism for glycoside bond hydrolysis and possibly gain insights into how the EDEM proteins are compromised in glycosidase activity, we generated mutations in the potential catalytic residues of human ERManI and examined their effects on substrate binding and catalysis. In parallel studies, we also examined the structure of a co-complex between human ERManI and an uncleavable thiodisaccharide substrate analog. These studies have yielded insights into the roles of active site residues and the dynamics of sugar conformational changes during glycoside bond hydrolysis.
Mutation of Glu 330 to an isosteric amide (E330Q) resulted in a significant decrease in k cat and a slight drop in K m similar to the effects seen in an equivalent mutant of S. cerevisiae ERManI (24) . Further analysis revealed a ϳ1.8-pH unit drop in the pH optimum and a drop in the calculated pK E values for both the acidic and basic limbs of the pH curve; however, the shifts in pK E values were more significant on the basic side of the curve. These data do not necessarily confirm a role of Glu 330 as the general acid in the catalytic mechanism, since the removal of the general acid might have been predicted to result in a grater loss in k cat and predominately influence the pK E of the basic limb of the pH curve by the loss of the ionizable residue. However, there are several nonstandard features of the general acid function for the GH47 ␣-mannosidases. First, the distance between the Glu 330 carboxyl side chain and the sulfur in the thiodisaccharide co-complex is far too large (ϳ4.2 Å) to account for direct protonation of the glycosidic oxygen of the substrate by the carboxyl side chain as is standard in both inverting and retaining glycosidases. Second, the presence of a weak density for an intervening water molecule, W8, as the only atom in proximity to the glycosidic oxygen would suggest that any general acid function would act indirectly in a through-water protonation mechanism. Third, Arg 334 is within ion-pairing distance from Glu 330 , supporting an interaction that should lower the pK a of Glu 330 rather than raise it to a value of ϳ7.8 as predicted from the pH rate studies (Fig. 3) . Fourth, both Glu 330 and Arg 334 are within hydrogen bonding distances of W8
( Fig. 7 and 5 -fold) than the E330Q mutant and a ϳ1000-fold loss in affinity for binding to dMNJ. Surprisingly, the drop in affinity for binding of the Man 9 GlcNAc 2 -glycopeptide substrate by SPR was only 4-fold, suggesting that the loss in catalytic turnover due to the absence of the catalytic base arose predominately from an unfavorable binding of the glycone residue in the Ϫ1 subsite rather than the docking of the Ͼϩ1 residues in the glycan binding cleft. Mutagenesis of the His residue adjacent to the Glu 599 catalytic base (H524A) reduced the k cat value by ϳ4-fold and slightly increased the K m , but the effects were relatively minor by comparison with those obtained for the conversion of the catalytic base to the isosteric amide. These data would indicate that Glu 599 acts as the catalytic base and that there is not a significant role of His 524 in the catalytic mechanism of ERManI.
The role of Asp 463 in the ERManI mechanism was tested by examining the kinetics and substrate binding of an isosteric amide mutant of the enzyme (D463N) and by examining the nature of the interactions between this residue and the substrate analog in the thiodisaccharide co-complex. The D463N mutant resulted in an ϳ800-fold drop in k cat , and binding of the Man 9 GlcNAc 2 -glycopeptide substrate to the enzyme was virtually eliminated as shown by SPR (Fig. 4) . In the co-crystal, Asp 463 was clearly seen to coordinate the ϩ1 residue by interacting with both the O-3Ј and O-4Ј hydroxyls of this residue (Fig. 7) . We anticipated that the isosteric amide substitution at this position (D463N) would allow hydrogen bonding capability to be retained while eliminating its potential role as a catalytic acid. Since this residue is clearly involved in stabilizing the interaction with the ϩ1 residue and does not act as a general acid, we were surprised that the mutation would have such a profound effect on substrate binding. Precedent for a significant decrease in bond length and increase in hydrogen bond strength for carboxylate side chains over isosteric amides has been previously noted (52) . The critical role of the proposed higher affinity interactions for the carboxylate over the amide would be strongly supported by a significant drop in k cat and the total loss of measurable binding affinity for high mannose oligosaccharides in the D463N mutant.
Standard glycosidase mechanisms invoke a glycone intermediate containing a partial positive charge delocalized between the anomeric carbon and the ring oxygen at or near the transition state. The partial double bond character requires coplanarity of the C-2-C-1-O-5-C-5 linkages (Fig. 1) . Of the four potential sugar ring conformers that satisfy these criteria (Fig.  1) , only the 3 H 4 conformer had not yet been identified as a potential glycosidase transition state conformation (14) . The unusual 1 C 4 conformation adopted by dMNJ in the ERManI⅐dMNJ co-complex has led to the suggestion that the family 47 glycosidases may employ a 3 H 4 transition state (14) . Evidence for this proposed transition state is provided here with the structure determination of the enzyme-bound thiodisaccharide pseudosubstrate which has been unambiguously shown to adopt a 3 S 1 skew boat conformation for the glycone in the Ϫ1 subsite. This conformation is quite different from that adopted in solution by unbound O-glycoside substrates or the thiodisaccharide analog. In the itinerary of sugar ring conformational interconversions, the 1 C 4 chair and 3 S 1 skew boat conformations bracket the 3 H 4 half-chair conformation (Figs. 1 and 6 ).
The co-complex structure described here demonstrates that the GH47 mannosidases bind to substrates constrained at the Ϫ1 residue into axial configurations for the C-3Ј and C-4Ј hydroxyls, and the C-5-C-6 linkage (Fig. 6) (Fig. 7A) . Most notably, the presence of Phe 659 at the base of the Ϫ1 subsite precludes the binding of a glycone residue containing equatorial configurations at C-4 and C-5 by steric hindrance. Additional interactions between the ϩ1 residue and Asp 463 play a critical role contributing to substrate binding affinity and in positioning the glycosidic linkage in proximity to the active site residues. Constraining the Ϫ1 residue into its high free energy 3 S 1 conformation would be predicted to reduce the activation energy needed for transformation of the substrate into the required (Fig. 6) . Collapse of the transition state would lead to a final product adopting a 1 C 4 chair conformation and an inverted anomeric configuration. In summary, these data are consistent with a mechanism of glycoside bond cleavage in which a least motion conformational twist of a properly predisposed substrate a Atom and residue numbering is based on equivalent residues in both the thiodisaccharide co-complex described here and the dMNJ co-complex with human ERManI (Protein Data Bank code 1FO2 (20) ). The ligand atoms refer to the equivalents of the O-2Ј and O-3Ј hydroxyl oxygens for the thiodisaccharide and dMNJ co-complexes in the respective columns.
at the Ϫ1 subsite accounts for the formation of the novel exploded transition state.
Modeling of the sequence of the non-catalytic family 47 ␣-mannosidase EDEM homologs upon a template of the human ERManI structure, surprisingly, did not result in a readily discernable difference in positions of any of the key catalytic residues (data not shown). Future studies on the nonhydrolytic EDEM proteins similar to those described here, which combine SPR binding studies with structural analysis of protein-glycan complexes, will hopefully reveal the structural basis of glycan recognition and ERAD targeting of unfolded glycoproteins by these lectins without catalyzing glycoside bond hydrolysis. 
